ANI Pharmaceuticals, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Nikhil Lalwani
- Full Time Employees
- 970
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 210 Main Street West Baudette MN United States of America 56623
- IPO Date
- May 5, 2000
- CIK
- 0001023024
- Website
- anipharmaceuticals.com
- Similar Companies
- Business
- ANI Pharmaceuticals, Inc. engages in the development, manufacturing, and commercialization of specialty generic pharmaceutical products, proprietary branded products, and rare disease therapies primarily in the United States. Its core products include generic oral solid and liquid dosage forms; specialty and branded pharmaceuticals focused on rare diseases such as Cortrophin Gel for multiple indications, Iluvien and YUTIQ ophthalmic implants; and prescription products in therapeutic areas including ophthalmology, pulmonology, rheumatology, neurology, and nephrology. The company also offers contract development and manufacturing services. Founded in 1971 and headquartered in Baudette, Minnesota, ANI serves healthcare providers, pharmacies, and specialty clinics. In recent years, ANI Pharmaceuticals has focused on expanding its rare disease and ophthalmology segments, marked by its 2024 acquisition of Alimera Sciences, which added the commercial ophthalmic brands Iluvien and YUTIQ, strengthening its presence in the ophthalmology market and boosting pro forma 2024 revenues by approximately $105 million. The acquisition supports an expanded ophthalmology sales team and contributed to robust growth in this therapeutic area. ANI has actively launched multiple generic products, including 14 new products in 2024 such as Promethazine Hydrochloride and Dextromethorphan Hydrobromide oral solution and Ketoconazole Shampoo, driving growth in its generics segment. The company also launched Estradiol Gel, 0.06% in late 2024 and Nitazoxanide Tablets in early 2025, targeting niche limited competition markets. ANI maintains a strong revenue growth trajectory, raising 2025 guidance to $843 million driven by strategic product launches and a strengthened rare disease portfolio. ANI Pharmaceuticals operates primarily in the pharmaceutical industry with segments focusing on generics, specialty pharmaceuticals, and rare diseases, targeting healthcare professionals and patient populations in the U.S. market. It benefits from a diversified product portfolio supported by a robust sales organization specialized in rare and specialty disease areas, backed by recent strategic financing supported by major financial institutions. The company continues to invest in expanding its commercial footprint and product offerings to maintain its leadership in niche pharmaceutical markets and rare therapeutic categories.
Company News
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Head to Head Comparison: ANI Pharmaceuticals (NASDAQ:ANIP) and Talphera (NASDAQ:TLPH)
ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting
Implied Volatility Surging for ANI Pharmaceuticals Stock Options
ANI Pharmaceuticals: Cortrophin's Q4 Test, With Generics Funding The Build
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Contrasting ANI Pharmaceuticals (NASDAQ:ANIP) and Cumberland Pharmaceuticals (NASDAQ:CPIX)
ANI Pharmaceuticals to Present at September Investor Conferences
ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors
Aurora Investment Counsel Takes Position in ANI Pharmaceuticals, Inc. $ANIP
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript
Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics
ANI Pharmaceuticals Q2 Earnings Call Highlights
ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates
ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results